(-)-Epigallocatechin Gallate [989-51-5]

Cat# HY-13653-1mL

Size : 10mM/1mL

Brand : MedChemExpress

Contact local distributor :


Phone : +1 850 650 7790

Description

(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].

IC50 & Target[1]

EGFR

 

HER2

 

HER3

 

Cellular Effect
Cell Line Type Value Description References
3T3-L1 IC50
112 μM
Compound: EGCG
Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry
Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry
[PMID: 23628332]
3T3-L1 IC50
25 μM
Compound: EGCG, (-)-epigalocatechin gallate
Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells
Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells
[PMID: 18313308]
A-431 EC50
266 μM
Compound: 1, EGCG
Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
A-431 EC50
38 μM
Compound: 1, EGCG
Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
A549 IC50
185 μM
Compound: EGCG
Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 31422225]
A549 IC50
29 μM
Compound: EGCG
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
BXPC-3 IC50
33 μM
Compound: EGCG
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
CHO IC50
271 μM
Compound: EGCG
Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay
Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay
[PMID: 23327877]
CHO IC50
3.2 μM
Compound: EGCG
Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay
Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay
[PMID: 23327877]
CHO IC50
7.7 μM
Compound: EGCG
Cytotoxicity against CHO cells expressing OATP1B1*1b after 48 hrs by fluorescence based CellTiter-Glo assay
Cytotoxicity against CHO cells expressing OATP1B1*1b after 48 hrs by fluorescence based CellTiter-Glo assay
[PMID: 23327877]
COLO 201 IC50
38 μM
Compound: EGCG
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
CV-1 IC50
12.05 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 isolate P27 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P27 infected in African green monkey CV1 cells
[PMID: 18195068]
CV-1 IC50
12.27 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 isolate P2 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P2 infected in African green monkey CV1 cells
[PMID: 18195068]
CV-1 IC50
12.47 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 isolate P22 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P22 infected in African green monkey CV1 cells
[PMID: 18195068]
CV-1 IC50
12.48 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 isolate P11 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P11 infected in African green monkey CV1 cells
[PMID: 18195068]
CV-1 IC50
12.5 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 isolate P12 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P12 infected in African green monkey CV1 cells
[PMID: 18195068]
CV-1 IC50
12.5 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 isolate P47 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P47 infected in African green monkey CV1 cells
[PMID: 18195068]
CV-1 IC50
25 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 2 strain 333 strain 333 infected in African green monkey CV-1 cells
Antiviral activity against Human herpesvirus 2 strain 333 strain 333 infected in African green monkey CV-1 cells
[PMID: 18195068]
H9 EC50
7 μg/mL
Compound: 8
Inhibition of HIV-1 replication in H9 (human lymphoma) cells.
Inhibition of HIV-1 replication in H9 (human lymphoma) cells.
10.1016/0960-894X(96)00095-9
H9 IC50
8 μg/mL
Compound: 8
Inhibition of uninfected H9 lymphocytic cell growth
Inhibition of uninfected H9 lymphocytic cell growth
10.1016/0960-894X(96)00095-9
HCT-116 IC50
161 μM
Compound: EGCG
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
[PMID: 12880319]
HCT-116 IC50
5 μM
Compound: 54
Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay
Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay
[PMID: 33445154]
HeLa IC50
1.08 μM
Compound: 4, EGCG
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol
[PMID: 22413845]
HeLa IC50
1.18 μM
Compound: 4, EGCG
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol
[PMID: 22413845]
HL-60 IC50
9.4 μM
Compound: EGCG
Antiproliferative activity against human HL60 cells after 3 days
Antiproliferative activity against human HL60 cells after 3 days
[PMID: 18693020]
HSC-T6 IC50
29.8 μM
Compound: EGCG
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability
[PMID: 25322455]
HSC-T6 IC50
31.6 μM
Compound: (-)-EGCG
Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay
Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay
[PMID: 28257196]
HSC-T6 IC50
9.9 μM
Compound: EGCG
Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay
Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay
[PMID: 18052323]
HSC-T6 IC50
9.9 μM
Compound: EGCG
Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay
Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay
[PMID: 21504848]
HT-22 IC50
23.8 μM
Compound: 42; EGCG
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
[PMID: 36876904]
HT-29 IC50
60 μM
Compound: EGCG
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
Huh-7 IC50
20 μM
Compound: 5, EGCG
Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay
Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay
[PMID: 25103601]
Jurkat IC50
1 μM
Compound: (-)-EGCG
Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis
Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis
[PMID: 30776692]
Jurkat IC50
18 μM
Compound: (-)-EGCG
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro
[PMID: 30776692]
L1210 IC50
690 μM
Compound: EGCG
Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay
Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay
[PMID: 18951028]
L929 IC50
82.3 μM
Compound: EGCG
Cytotoxicity against mouse L929 cells after 3 days by MTS assay
Cytotoxicity against mouse L929 cells after 3 days by MTS assay
[PMID: 25985195]
LN-229 IC50
15 μM
Compound: EGCG
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
LX-2 CC50
>100 μM
Compound: EGCG
Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay
Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay
[PMID: 34610571]
MCF7 IC50
4 μM
Compound: EGCG
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
[PMID: 30048133]
MCF7 IC50
74 μM
Compound: 38; ECGC
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
[PMID: 31663736]
MCF7 IC50
74 μM
Compound: EGCG, 38
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
[PMID: 25141341]
MDA-MB-231 IC50
149 μM
Compound: 1; EGCG
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
[PMID: 37776575]
MDA-MB-231 IC50
76.1 μM
Compound: EGCG
Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
[PMID: 25453798]
MDA-MB-231 IC50
83 μM
Compound: EGCG
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
MDCK CC50
>100 μM
Compound: EGCG
Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
[PMID: 36521178]
MDCK CC50
>200 μM
Compound: EGCG
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 31954881]
MDCK CC50
275 μM
Compound: 1, EGCG
Cytotoxicity against MDCK cells by MTT assay
Cytotoxicity against MDCK cells by MTT assay
[PMID: 18547804]
MDCK CC50
275.4 μM
Compound: 56; EGCG
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
[PMID: 28118010]
MDCK EC50
94.6 μM
Compound: 1, EGCG
Antiviral activity against Influenza A/PR8/34(H1N1)) in dog MDCK cells
Antiviral activity against Influenza A/PR8/34(H1N1)) in dog MDCK cells
[PMID: 18547804]
MDCK ED50
8.3 μM
Compound: 3, EGCG
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR
[PMID: 22115591]
MDCK IC50
41.25 μM
Compound: 1, EGCG
Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay
Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay
[PMID: 17420124]
MEF GI50
14 μM
Compound: 34, EGCG
Growth inhibition of Pin1-deficient MEF
Growth inhibition of Pin1-deficient MEF
[PMID: 23796453]
MEF GI50
7 μM
Compound: 34, EGCG
Growth inhibition of MEF expressing Pin1
Growth inhibition of MEF expressing Pin1
[PMID: 23796453]
NCI-H1299 IC50
>80 μM
Compound: EGCG
Antiproliferative activity in human NCI-H1299 cells after 72 hrs
Antiproliferative activity in human NCI-H1299 cells after 72 hrs
[PMID: 29530347]
NCI-H1299 IC50
20.6 μM
Compound: EGCG
Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 31422225]
NCI-H1650 IC50
24.8 μM
Compound: EGCG
Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 31422225]
NCI-H1703 IC50
17.1 μM
Compound: EGCG
Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 31422225]
NCI-H460 IC50
18 μM
Compound: EGCG
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
PANC-1 IC50
62 μM
Compound: EGCG
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
PC-12 IC50
0.03 μM
Compound: 69; (-)-EGCG
Neuroprotective activity against rat PC12 cells assessed as decrease in H2O2-induced intracellular Ca2+ level preincubated for 12 hrs followed by H2O2-stimulation and measured after 12 hrs by Fluo-3 AM dye based flow cytometry
Neuroprotective activity against rat PC12 cells assessed as decrease in H2O2-induced intracellular Ca2+ level preincubated for 12 hrs followed by H2O2-stimulation and measured after 12 hrs by Fluo-3 AM dye based flow cytometry
[PMID: 38295689]
PC-9 IC50
77.4 μM
Compound: EGCG
Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 31422225]
Peritoneal macrophage cell IC50
436.3 μM
Compound: 1, EGCG
Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay
Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay
[PMID: 24106750]
RAW264.7 IC50
29.8 μM
Compound: EGCG
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days
[PMID: 21456521]
Sf9 IC50
0.5 μM
Compound: 9, EGCG
Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil
Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil
[PMID: 25406944]
SH-SY5Y EC50
39.87 nM
Compound: EGCG
Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release
Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release
[PMID: 19138859]
SK-BR-3 EC50
100 μM
Compound: 1, EGCG
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
SK-BR-3 EC50
195 μM
Compound: 1, EGCG
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
SK-BR-3 IC50
149 μM
Compound: 4, EGCG
Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay
[PMID: 22559865]
SK-BR-3 IC50
150 μM
Compound: 27, EGCG
Cytotoxicity against human SKBR3 cells
Cytotoxicity against human SKBR3 cells
[PMID: 21726077]
SK-BR-3 IC50
4 μM
Compound: EGCG
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
[PMID: 30048133]
SK-MEL-2 IC50
31 μM
Compound: EGCG
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
SW480 IC50
195 μM
Compound: EGCG
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
[PMID: 12880319]
T47D IC50
57 μM
Compound: EGCG
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
T98G IC50
166 μM
Compound: EGCG
Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay
Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay
[PMID: 26631318]
U-266 IC50
23.2 μM
Compound: 52; EGCG
Induction of nitric oxide production in human U266 cells
Induction of nitric oxide production in human U266 cells
[PMID: 31330448]
U-87MG ATCC IC50
18 μM
Compound: EGCG
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
U-937 IC50
1 μM
Compound: 4, EGCG
Inhibition of telomerase in human U937 cells
Inhibition of telomerase in human U937 cells
[PMID: 22413845]
Vero IC50
16 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 isolate P32 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P32 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
Vero IC50
18.3 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 isolate P56 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P56 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
Vero IC50
45.36 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 isolate P25 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P25 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
Vero IC50
48.18 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 isolate P38 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P38 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
Vero IC50
48.41 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 isolate P15 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P15 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
Vero IC50
49.09 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 isolate P42 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P42 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
Vero IC50
72.3 μM
Compound: (-)-EGCG
Antiviral activity against Human herpesvirus 1 F1 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 F1 infected in African green monkey vero cells assessed as reduction in viral titer
[PMID: 18195068]
In Vitro

(-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner[1].
(-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression[1].
(-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration[1].
(-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)[2].
(-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase[3].
(-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: FB-2 and WRO cells (serum-starved for 48h)
Concentration: 10, 40, 60 μM.
Incubation Time: 4 days
Result: Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).

Western Blot Analysis[1]

Cell Line: FB-2 cells
Concentration: 10, 40, 60 μM.
Incubation Time: 24 h
Result: Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2.
Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin.

Cell Migration Assay [1]

Cell Line: FB-2 and WRO cells (serum-starved for 48h)
Concentration: 10, 40, 60 μM.
Incubation Time: 12 h
Result: Reduced migration activity in FB-2 and WRO cells.

RT-PCR[4]

Cell Line: Mouse primary osteoblasts (1 ng/ml LPS-treated)
Concentration: 30 μM
Incubation Time: 3, 6, 12, 24 h
Result: Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.
In Vivo

(-)-Epigallocatechin Gallate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth[3].
(-)-Epigallocatechin Gallate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Orthotopic transplant BALB/c nude mice model[3]
Dosage: 5, 10, and 20 mg/kg, once daily for 14 days.
Administration: Intragastrical administration.
Result: Inhibited tumors growth with no liver or lung metastases.
Animal Model: Model of experimental periodontitis, LPS (25 μg/mouse)[4]
Dosage: 0.5 mg/mouse, a single dose.
Administration: Injected into the mouse lower gingiva
Result: Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.
Molecular Weight

458.37

Formula

C22H18O11

CAS No.
Appearance

Solid

Color

Off-white to pink

SMILES

O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 70 mg/mL (152.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1816 mL 10.9082 mL 21.8164 mL
5 mM 0.4363 mL 2.1816 mL 4.3633 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  0.5% CMC/saline water

    Solubility: 10 mg/mL (21.82 mM); Suspended solution; Need ultrasonic

Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-14590-50mg
 50mg 
HY-14590-100mg
 100mg